These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31689714)

  • 1. Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents.
    Harada A; Kaushal N; Suzuki K; Nakatani A; Bobkov K; Vekich JA; Doyle JP; Kimura H
    Int J Neuropsychopharmacol; 2020 Feb; 23(2):96-107. PubMed ID: 31689714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
    Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
    Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats.
    Nakatani A; Nakamura S; Kimura H
    Neurosci Res; 2017 Dec; 125():29-36. PubMed ID: 28687229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.
    Wilson JM; Ogden AM; Loomis S; Gilmour G; Baucum AJ; Belecky-Adams TL; Merchant KM
    Neuropharmacology; 2015 Dec; 99():379-86. PubMed ID: 26256420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.
    Gresack JE; Seymour PA; Schmidt CJ; Risbrough VB
    Psychopharmacology (Berl); 2014 May; 231(10):2189-97. PubMed ID: 24363077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
    Suzuki K; Harada A; Suzuki H; Capuani C; Ugolini A; Corsi M; Kimura H
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
    Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
    Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.
    Gentzel RC; Toolan D; Roberts R; Koser AJ; Kandebo M; Hershey J; Renger JJ; Uslaner J; Smith SM
    Neuropharmacology; 2015 Dec; 99():256-63. PubMed ID: 26044638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.
    Hsu YT; Liao G; Bi X; Oka T; Tamura S; Baudry M
    Neuropharmacology; 2011 Dec; 61(8):1275-81. PubMed ID: 21816164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
    Suzuki K; Harada A; Shiraishi E; Kimura H
    J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of PDE10 inhibition on attentional set-shifting do not depend on the activation of dopamine D1 receptors.
    Nikiforuk A; Potasiewicz A; Rafa D; Drescher K; Bespalov A; Popik P
    Behav Pharmacol; 2016 Jun; 27(4):331-8. PubMed ID: 26580130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
    Wei W; Ding S; Zhou FM
    J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
    D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
    J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation.
    Threlfell S; Sammut S; Menniti FS; Schmidt CJ; West AR
    J Pharmacol Exp Ther; 2009 Mar; 328(3):785-95. PubMed ID: 19056933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.
    Bordia T; Zhang D; Perez XA; Quik M
    Exp Neurol; 2016 Dec; 286():32-39. PubMed ID: 27658674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.
    Schier CJ; Marks WD; Paris JJ; Barbour AJ; McLane VD; Maragos WF; McQuiston AR; Knapp PE; Hauser KF
    J Neurosci; 2017 Jun; 37(23):5758-5769. PubMed ID: 28473642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal Distribution and Cytoarchitecture of Dopamine Receptor Subtype 1 and 2: Evidence from Double-Labeling Transgenic Mice.
    Ren K; Guo B; Dai C; Yao H; Sun T; Liu X; Bai Z; Wang W; Wu S
    Front Neural Circuits; 2017; 11():57. PubMed ID: 28860974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D
    Arakawa K; Nakao K; Maehara S
    Behav Brain Res; 2017 Jan; 317():204-209. PubMed ID: 27659554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32.
    Polito M; Guiot E; Gangarossa G; Longueville S; Doulazmi M; Valjent E; Hervé D; Girault JA; Paupardin-Tritsch D; Castro LR; Vincent P
    eNeuro; 2015; 2(4):. PubMed ID: 26465004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.